Financials data is unavailable for this security.
View more
Year on year Aclaris Therapeutics Inc grew revenues 5.03% from 29.75m to 31.25m while net income improved from a loss of 86.91m to a smaller loss of 88.48m.
| Gross margin | 53.53% |
|---|---|
| Net profit margin | -136.65% |
| Operating margin | -170.99% |
| Return on assets | -18.47% |
|---|---|
| Return on equity | -25.83% |
| Return on investment | -20.87% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Aclaris Therapeutics Inc fell by 5.40m. However, Cash Flow from Investing totalled 46.22m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 78.33m for operations while cash generated from financing totalled 26.71m.
| Cash flow per share | -0.5072 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.82 |
|---|---|
| Tangible book value per share | 1.82 |
More ▼
Balance sheet in USDView more
| Current ratio | 7.03 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
